Artificial Intelligence May Help Personalize Insulin Dosing for Type 1 Diabetes

Everyone with type 1 diabetes experiences glucose differently. What causes a blood sugar spike for one person might have minimal effect on another. Stress, sleep, exercise, food timing, and hormonal changes all influence how quickly insulin works and how the body responds to meals.

Traditional insulin regimens use fixed doses based on general guidelines. While these help many people, they cannot adjust moment-to-moment to life's unpredictability. This gap between rigid dosing and real-world complexity is why blood sugar control remains challenging for many people with type 1 diabetes.

Researchers recently developed an artificial intelligence system designed to learn from a person's unique glucose patterns and suggest personalized insulin adjustments in real time. The system, called a deep Q-network, analyzes continuous glucose monitor data along with information about meals and physical activity.

The AI focuses on a 2-hour window of data, which aligns with how rapidly-acting insulin typically works in the body (peak action within 90–120 minutes). By examining recent glucose levels, insulin doses, and lifestyle factors together, the system aims to recommend adjustments that work for that individual's metabolism.

The study used 8 weeks of data from twelve people with type 1 diabetes, including continuous glucose measurements, insulin records, and activity levels. This dataset, called the OhioT1DM dataset, comes from real-world glucose management situations.

The research was published in the peer-reviewed journal JMIR Diabetes in June 2026. While promising, this remains early-stage work. Much more research is needed before this approach could become part of standard diabetes care.

If further research supports these early findings, personalized AI-guided dosing could help people achieve better glucose control with fewer dangerous blood sugar lows. The system's ability to adapt continuously might reduce the burden of constant manual calculations and decision-making.

It is important to note that this is laboratory research. The technology is not currently available for clinical use, and many questions remain about how well it would work across diverse populations, different insulin types, and varying life circumstances. Any future diabetes technology would need rigorous testing and approval before becoming standard care.

Source: JMIR diabetes. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.